Medicago
7 Durham Triangle Dr.
Durham
North Carolina
27713
United States
Tel: 1-919-313-9670
Website: https://medicago.com/en/
About Medicago
Medicago believes in the power of plants to help protect public health. Our journey started in 1999 with one objective: to help protect human life and today, we are a leader in developing vaccines and therapeutics manufactured in plants. Our plant-based technology allows us to swiftly develop vaccines and therapies that can respond to pandemic situations and endemic diseases.
Our platform develops both vaccine and antibody candidates and is one of the few in the world with this capability. As Medicago continues with the research and development of vaccine candidates to help protect human health against viruses, we seek to expand our scope beyond viral diseases.
Our teams are working to develop vaccines, antibodies and therapeutic proteins that can be used, among other things, to fight infectious diseases and cancers. Medicago’s vaccine production platform is also capable of producing monoclonal antibodies artificially produced to treat a disease.
At Medicago, we’re proud of our humble beginnings as well as our evolution from an R&D company to bringing our first commercial products to market. We are growing our global capabilities but our roots in Quebec and Canada will always remain. Medicago has been a privately-held company since 2013.
CONNECT
31 articles with Medicago
-
Pfizer's Paxlovid racks up a rare trial miss, Medicago and GSK publish positive data for their plant-based particle vaccine and Rhythm Pharmaceuticals touts strong potential in Bardet-Biedl Syndrome.
-
Despite having infinitely better global communications, exact figures are hard to come by for COVID-19 fatalities. Here's a look at that story and more COVID-19 news.
-
Medicago announces the appointment of Toshifumi Tada as President and CEO
4/28/2022
Medicago, a biopharmaceutical company headquartered in Quebec City, Canada, announced the appointment of Toshifumi Tada as President and chief executive officer, effective on May 1, 2022.
-
There is some evidence that COVID-19 infection might be linked to an increase in diabetes, particularly Type 1 diabetes, which is an autoimmune disease most commonly diagnosed in children.
-
Not only is this the first approval for a plant-based vaccine, it’s also the first approval for GSK’s adjuvant.
-
Medicago and GSK announce the approval by Health Canada of COVIFENZ, an Adjuvanted Plant-Based COVID-19 Vaccine
2/24/2022
Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) today announced that Health Canada has granted approval for COVIFENZ®, COVID-19 vaccine, (plant-based virus-like particles [VLP], recombinant, adjuvanted).
-
Medicago and GSK Announce the Approval by Health Canada of COVIFENZ®, an Adjuvanted Plant-Based COVID-19 Vaccine
2/24/2022
Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) today announced that Health Canada has granted approval for COVIFENZ®, COVID-19 vaccine, (plant-based virus-like particles [VLP], recombinant, adjuvanted).
-
Medicago submits Phase 3 data to Health Canada for its plant-based COVID-19 vaccine candidate
12/16/2021
Medicago, a biopharmaceutical company headquartered in Quebec City, is pleased to announce submission of the positive Phase 3 data for regulatory review by Health Canada as part of the New Drug Submission for COVID (NDS-CV) rolling review for Medicago’s COVID-19 vaccine candidate combined with GSK’s pandemic adjuvant.
-
Medicago and GSK announce positive interim Phase 2 results for adjuvanted COVID-19 vaccine candidate
5/18/2021
Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline are pleased to report positive interim Phase 2 clinical trial safety and immunogenicity data for Medicago's plant-derived COVID-19 vaccine candidate, which has been tested in combination with GSK's pandemic adjuvant.
-
Medicago and GSK announced their positive interim data from a mid-range study of a plant-based vaccine for COVID-19.
-
Health Canada initiates the review of the rolling submission for the first Canadian-based COVID-19 vaccine candidate
4/23/2021
Medicago, a biopharmaceutical company headquartered in Quebec City is pleased to announce that Health Canada received for review the first portion of Medicago's plant-derived COVID-19 vaccine candidate rolling submission on April 19, 2021.
-
Clinical Catch-Up: March 15-19
3/22/2021
It was a relatively quiet week in terms of clinical trial news, but there were some significant releases. Here’s a look. -
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Medicago and GSK start Phase 3 trial of adjuvanted COVID-19 vaccine candidate
3/16/2021
Medicago, a biopharmaceutical company headquartered in Quebec City and GlaxoSmithKline, are pleased to announce the start of Phase 3 clinical testing of Medicago's plant-derived COVID-19 vaccine candidate in combination with GSK's pandemic adjuvant, as part of the ongoing Phase 2/3 study.
-
BioSpace Global Roundup, Nov. 12
11/12/2020
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines. -
Medicago announces positive Phase 1 results for its COVID-19 vaccine candidate
11/10/2020
Medicago, a biopharmaceutical company headquartered in Quebec City , is pleased to report interim results of the Phase 1 clinical trial of its plant-derived vaccine for COVID-19. The resu
-
Medicago signs agreements with the Government of Canada to supply up to 76 million doses of its recombinant plant-derived COVID-19 vaccine
10/23/2020
Canadian government to provide $173M in funding for vaccine research and development, and domestic manufacturing capacity
-
Clinical Catch-Up: July 13-17
7/20/2020
It was a surprisingly big week for clinical trial updates related to COVID-19, although there was plenty of non-COVID-19 news as well. Here’s a look. -
BioSpace Global Roundup, July 16
7/16/2020
Biopharma and life sciences companies from across the globe provide updates on their business and pipelines. -
Medicago begins Phase I clinical trials for its COVID-19 vaccine candidate
7/14/2020
Medicago, a biopharmaceutical company headquartered in Quebec City, began Phase I clinical trials for its plant-derived COVID-19 vaccine candidate yesterday, administering the first doses in healthy human volunteers